Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying brenipatide LY3537031 to evaluate its safety, side effects, and effectiveness in adults with Irritable Bowel Syndrome-Constipation IBS-C. The study compares brenipatide given by injection under the skin to a placebo in a phase 2 clinical trial. Participants must meet specific IBS-C criteria and have significant abdominal pain to join. Participants receive the study drug or placebo through subcutaneous injection. The trial lasts about 36 weeks, with treatment and monitoring occurring during this period. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will keep a daily diary to track symptoms like abdominal pain and bowel movements. Researchers will measure the percentage of weeks participants respond to treatment based on clinical criteria between weeks 9 and 16. Safety and side effects will also be closely monitored throughout the trial.
Actively Recruiting
Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.
Actively Recruiting
Healthy Volunteer
This research aims to develop and evaluate a stepwise screening approach for early detection of Alzheimers disease AD in community populations aged 50 and above. The study addresses the growing global burden of AD, which accounts for 60-80% of dementia cases worldwide, with a focus on scalable, accessible methods suitable for low- and middle-income settings. The study integrates digital cognitive assessments and blood-based biomarkers to improve early diagnosis during the prolonged preclinical phase of the disease. The screening process involves two main steps. The first step uses digital tools including the SCD-9 questionnaire to capture subjective cognitive complaints, a digital cognitive test PCAT assessing memory and symbol matching, and a predictive model for future dementia risk. The second step confirms AD pathology through blood-based biomarkers, comparing multiple candidates such as p-tau217, p-tau181, and A240 measured via assay platforms like Simoa and CLEIA. Amyloid PET scans serve as the gold standard for AD pathology confirmation. Participants will be community residents aged 50 years or older, without prior cognitive impairment or anti-dementia drug use, and able to communicate in Chinese. Researchers will collect and analyze data on screening sensitivity and specificity, program completion, time to completion, community feasibility, compliance, and cost-effectiveness. The study spans multiple centers nationwide and involves clinical dementia rating assessments and biomarker testing, with the goal of creating a model applicable to primary healthcare systems in developing countries.
Actively Recruiting
Researchers are studying the safety and effectiveness of early use of tirofiban in patients who have acute ischemic stroke and are treated with tenecteplase. This study is exploring whether adding tirofiban soon after tenecteplase can reduce the risk of blood clot re-blockage in the brain, which happens in some patients after initial treatment. The study is a phase 3 trial aiming to improve stroke outcomes by preventing this reocclusion. Participants first receive tenecteplase intravenously for stroke treatment. Those who meet the study criteria are then randomly assigned to receive either tirofiban or a placebo. Tirofiban or placebo is given intravenously starting as soon as possible after randomization, initially as a higher dose for 30 minutes, followed by a continuous lower dose infusion for nearly 48 hours. After 24 hours, patients receive aspirin andor clopidogrel or their placebos, then after 44 hours, antiplatelet therapy with aspirin andor clopidogrel continues until the 90-day follow-up. During the study, participants undergo assessments including neurological exams and monitoring for bleeding or other adverse events. The main outcome measured is excellent functional recovery 90 days after randomization. Other outcomes include disability levels, neurological improvement, quality of life, bleeding events, and mortality. Safety and serious adverse events are tracked through the 90-day period to evaluate treatment effects and risks.
Actively Recruiting
Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SG301 SC Injection in people diagnosed with Systemic Lupus Erythematosus SLE. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to measure how well the treatment works based on the Systemic Lupus Erythematosus Responder Index -4 SRI-4 response rate. Secondary goals include assessing the safety, how the drug is processed in the body, and its immune effects. Participants will receive SG301 SC Injection or a placebo through a series of 16 subcutaneous injections. The dosing schedule starts with one injection per week for 8 weeks, followed by injections every two weeks for another 8 doses. Some participants may receive placebo injections mixed within the treatment regimen. The study is designed with parallel groups and includes careful monitoring of drug effects and immune responses. During the study, participants will be regularly evaluated for disease activity, side effects, and immune responses. The main measure of success is the proportion of participants achieving an improved SRI-4 score from baseline to week 25. Study visits will include clinical assessments and safety monitoring. The total participant involvement extends through the treatment period and follow-up until study completion, expected by the end of 2027.